Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04564274 · ClinicalTrials.gov registry record

COV2Base-A Rare Disease by COVID Study

A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
1,748
Enrollment target

NCT04564274 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,748 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04564274 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
1,748 participants
Enrollment target

Study Summary

Background: SARS-CoV-2 is the virus that causes COVID. It has caused a global pandemic. Most people have no to mild symptoms. But some people need to be hospitalized, and a small number need critical care. Older age as well as some socio-demographic factors and chronic health conditions may play a role in the severity of COVID. In this study, researchers want to assess sociodemographic-, population-, disease-, and gene-based risks for features associated with severe SARS-CoV-2 outcomes. As more is understood about COVID, researchers also want to learn more about people s experiences with COVID vaccines, long-haul symptoms, and other related disease features. Objective: To measure the frequency and severity of COVID infection in people with rare and common diseases, looking for conditions that increase risk of severe outcomes. To describe experiences with COVID vaccines, symptoms, and other features of COVID in people with rare and common diseases. Eligibility: People greater than 1 month of age, both with and without rare disease, who have access to the Internet. Design: This study will take place online. Participants will visit a website. They will fill out a survey. It should take less than 30 minutes to complete. They will answer questions about their current health and COVID experiences. They will answer questions about their demographic and location features that may impact their exposure to the virus. All questions are optional. Participants may repeat the survey if their responses indicate a need for follow-up. Participants medical records may be reviewed. Participants may be contacted for future studies related to: COVID Their underlying health conditions A new exposure that is being studied....

Trial Details

FieldValue
Enrollment Target 1,748 participants
Start Date 2020-10-04
Est. Completion 2022-05-20

What the Registry Record Tells You About NCT04564274

The ClinicalTrials.gov registry entry for NCT04564274 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,748 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04564274 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04564274 about?

NCT04564274 is a clinical study titled "COV2Base-A Rare Disease by COVID Study". Background: SARS-CoV-2 is the virus that causes COVID. It has caused a global pandemic. Most people have no to mild symptoms. But some people need to be hospitalized, and a small number need critical care. Older age as well as some socio-demographic factors and chronic health conditions may play a ...

What is the current status of trial NCT04564274?

This trial is currently completed. The enrollment target is 1,748 participants. The study started on 2020-10-04. Estimated completion is 2022-05-20.

Who is sponsoring clinical trial NCT04564274?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.